Subcutaneous adipose tissue is a positive predictor for bone mineral density in prepubertal children with Prader-Willi syndrome independent of lean mass
- PMID: 35286052
- DOI: 10.1515/jpem-2021-0749
Subcutaneous adipose tissue is a positive predictor for bone mineral density in prepubertal children with Prader-Willi syndrome independent of lean mass
Abstract
Objectives: Emerging evidence suggests a fat depot-specific relationship with bone mineral density (BMD) in children, particularly in those who are overweight/obese. However, this has not yet been investigated in detail in children with Prader-Willi syndrome (PWS), a genetic syndrome characterized by a decreased lean mass (LM) and increased fat mass (FM). The objective of this study is to investigate the relationships of LM and FM, particularly fat distribution, with bone mineral parameters.
Methods: This is a retrospective and cross-sectional study. Forty-seven prepubertal Japanese children with PWS (22 males, mean age: 6.86 years) were included. No subjects had type 2 diabetes mellitus or osteoporotic medications. LM, FM, and BMD and bone mineral content in the total body less head and the lumbar spine were measured using dual-energy x-ray absorptiometry, in addition to subcutaneous/visceral adipose tissue (SAT/VAT), and the ratio of VAT to SAT (V/S) by computed tomography at the umbilical level. Bone mineral apparent density was calculated to correct for bone size.
Results: LM positively correlated with bone mineral parameters after controlling for age, sex, growth hormone (GH) treatment, and FM. Although FM did not correlate with bone mineral parameters, compartment-specific analysis revealed that SAT positively and V/S negatively correlated with bone mineral parameters after controlling for age, sex, GH treatment and LM.
Conclusions: A compartment-specific effect of FM on bone mineral parameters was noted such that SAT was a positive predictor for BMD independent of LM in prepubertal children with PWS.
Keywords: Prader–Willi syndrome; adiposity; bone mineral density; children; fat distribution.
© 2022 Walter de Gruyter GmbH, Berlin/Boston.
References
-
- Cassidy, SB, Schwartz, S, Miller, JL, Driscoll, DJ. Prader–Willi syndrome. Genet Med 2012;14:10–26, https://doi.org/10.1038/gim.0b013e31822bead0.
-
- Irizarry, KA, Miller, M, Freemark, M, Haqq, AM. Prader Willi syndrome: genetics, metabolomics, hormonal function, and new approaches to therapy. Adv Pediatr 2016;63:47–77, https://doi.org/10.1016/j.yapd.2016.04.005.
-
- Passone, CGB, Franco, RR, Ito, SS, Trindade, E, Polak, M, Damiani, D, et al.. Growth hormone treatment in Prader–Willi syndrome patients: systematic review and meta-analysis. BMJ Paediatr Open 2020;4: e000630, https://doi.org/10.1136/bmjpo-2019-000630.
-
- Deal, CL, Tony, M, Hoybye, C, Allen, DB, Tauber, M, Christiansen, JS. Growth hormone research society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader–Willi syndrome. J Clin Endocrinol Metab 2013;98:E1072–87, https://doi.org/10.1210/jc.2012-3888.
-
- Vestergaard, P, Kristensen, K, Bruun, JM, Ostergaard, JR, Heickendorff, L, Mosekilde, L, et al.. Reduced bone mineral density and increased bone turnover in Prader-Willi syndrome compared with controls matched for sex and body mass index--a cross-sectional study. J Pediatr 2004;144:614–9, https://doi.org/10.1016/j.jpeds.2004.01.056.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials